ACC 2020: The VICTORIA Trial — Dr Paul W Armstrong & Dr Harriette Van Spall

In this interview with Dr Harriette Van Spall (McMaster University, Hamilton, CA) asks Dr Paul W Armstrong (Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, CA) about the VICTORIA trial. The objective of the Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction trial (VICTORIA) was to assess whether vericiguat reduced the primary composite outcome of cardiovascular (CV) death or first HF hospitalisation.